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ABSTRACT (246/250 words) 29 
 30 
OBJECTIVE: Osteoarthritis (OA) is a major source of knee pain. Mechanisms of OA knee 31 
pain are incompletely understood but include synovial pathology. We aimed to identify 32 
molecular expression patterns in the synovium associated with symptomatic knee OA. 33 
DESIGN: Snap frozen synovia were from people undergoing total knee replacement (TKR) 34 
for advanced OA, or from post-mortem (PM) cases who had not sought help for knee pain. 35 
Associations with OA symptoms were determined using discovery and validation samples, 36 
each comprising TKR and PM cases matched for chondropathy (Symptomatic or 37 
Asymptomatic Chondropathy). Associations with OA were determined by comparing age 38 
matched TKR and PM control cases. Real-time quantitative PCR for 96 genes involved in 39 
inflammation and nerve sensitisation used TaqMan® Array Cards in discovery and validation 40 
samples, and protein expression for replicated genes was quantified using Luminex bead 41 
assay. 42 
RESULTS: Eight genes were differentially expressed between asymptomatic and 43 
symptomatic chondropathy cases and replicated between discovery and validation samples 44 
(P<0.05 or > 3-fold change). Of these, matrix metalloprotease (MMP)-1 was also increased 45 
whereas interleukin-1 receptor 1 (IL1R1) and vascular endothelial growth factor (VEGF) 46 
were decreased at the protein level in the synovium of symptomatic compared to 47 
asymptomatic chondropathy cases. MMP1 protein expression was also increased in OA 48 
compared to PM controls. 49 
CONCLUSION: Associations of symptomatic OA may suggest roles of MMP1 expression 50 
and IL1R1 and VEGF pathways in OA pain. Better understanding of which inflammation-51 
associated molecules mediate OA pain should inform refinement of existing therapies and 52 
development of new treatments. 53 
KEY WORDS: Osteoarthritis, Pain, Synovitis, Gene expression 54 
  55 
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INTRODUCTION 56 
Knee osteoarthritis (OA) is a complex disease involving all joint tissues. Mechanisms of OA 57 
knee pain are incompletely understood, but can include synovial pathology [1-3] and 58 
subchondral bone [4].  Inflammatory mediators from the synovium activate or sensitise 59 
nociceptors through downstream signalling pathways. Nerve terminal sensitisation leads 60 
stimuli that would not usually elicit pain to be perceived as painful. Understanding molecular 61 
expression patterns that contribute to symptomatic OA is crucial to developing new analgesic 62 
treatment strategies, and to focus disease modification strategies on those which are most 63 
likely to improve symptoms. 64 
Numerous inflammatory mediators such as cytokines, chemokines, growth factors, and 65 
matrix metalloproteinase (MMPs) released from synoviocytes during inflammation might 66 
contribute to OA pain. Key roles have been suggested for the pro-inflammatory cytokines 67 
interleukin (IL)-1β and tumour necrosis factor (TNF)-α in mediating pain through the release 68 
of other downstream inflammatory mediators such as matrix metalloproteases (MMPs) and 69 
cytokines [5].  The effects of IL-1β are mediated through binding to IL-1 receptor type 1 70 
(IL1R1). Pain has been associated with increased TNF-α [6], chemokine ligand 2 (CCL2), 71 
chemokine ligand 4 (CCL4), IL-6 and interferon-γ [7] in synovial fluid. Vascular endothelial 72 
growth factor (VEGF), a potent stimulator of angiogenesis involved in neuropathic pain [8], 73 
is increased in OA synovium [9, 10] and associated with OA pain and progression [11]. 74 
MMP1 is an interstitial collagenase that is elevated in synovial fluid from people with OA 75 
[12]. The nuclear factor kappa-B (NF-κB) is part of a downstream signalling pathway which 76 
contributes to the up-regulation of various pro-inflammatory and angiogenic factors [13]. 77 
Recent work has identified differences in gene expression patterns of inflammatory cytokines 78 
between inflamed and non-inflamed areas of synovia from people with OA [14, 15]. We 79 
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hypothesised that specific molecular patterns in the synovium are associated with 80 
symptomatic OA, indicating possible molecular mechanisms of OA pain.  Gene and protein 81 
expression patterns in the synovium were compared between groups of people with similar 82 
macroscopic appearances of the tibiofemoral articular surfaces who had either sought TKR 83 
for OA symptoms (symptomatic chondropathy) or had not sought help for OA knee pain 84 
before death (asymptomatic chondropathy), and between people with or without OA. The 85 
rationale for comparing people with or without OA was to define whether signatures 86 
identified as characteristic of symptomatic OA were also characteristics of OA. Pain in OA 87 
might be due to aspects of OA pathology which mediate pain, or due to concurrent pathology 88 
which, in the context of OA, is painful. 89 
METHOD 90 
This cross-sectional study was approved by Nottingham Research Ethics Committee 1 91 
(05/Q2403/24) and Derby Research Ethics Committee 1 (11/H0405/2). 92 
Patients 93 
Total knee replacement groups 94 
Snap frozen synovium samples were collected at total knee replacement (TKR) surgery for 95 
symptomatic OA (‘OA’ or ‘symptomatic chondropathy’ groups). All TKR cases satisfied the 96 
American College of Rheumatology classification criteria for knee OA at the time of surgery 97 
[16] but groups differed only in that the OA group comprised cases aged-matched to post 98 
mortem (PM) controls, whereas the symptomatic chondropathy group was matched to the 99 
asymptomatic chondropathy group for macroscopic scoring of cartilage surface changes [17]. 100 
All in the OA group had a Kellgren Lawrence radiographic score ≥2.  101 
 102 
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Post-mortem (PM) groups 103 
Three sample groups were selected from post-mortem (PM) cases who did not have arthritis 104 
and had not reported knee pain during the last year of their life (‘PM control’, ‘non-arthritic 105 
control’ and ‘asymptomatic chondropathy’ groups).  106 
The PM control group were selected as consecutive aged matched cases to the OA group and 107 
did not include cases with macroscopic chondropathy lesions of grade 4 (subchondral bone 108 
exposure) in the medial tibiofemoral compartment [17].  109 
Inclusion criteria for the non-arthritic control group were no osteophytes in the dissected 110 
knee, no Heberden’s nodes (because these may be associated with knee OA incidence and 111 
progression [18]) and no macroscopic chondropathy lesions grade ≥3 in the medial 112 
tibiofemoral compartment [3].  113 
Molecular associations with OA symptoms  114 
Associations of gene expression with symptoms were determined using discovery 115 
(n=12/group) and validation samples (n = 10/group), each comprising symptomatic and 116 
asymptomatic chondropathy groups. Discovery and validation samples were combined to 117 
compare protein expression between asymptomatic (n=22) and symptomatic (n=22) 118 
chondropathy groups (supplementary figure 1A).  119 
Molecular associations with OA disease status  120 
The following age-matched (within 7 years) control PM groups and OA groups were 121 
compared to determine associations with OA disease status: 122 
1) Non-arthritic control vs. symptomatic chondropathy (n = 10/group) for gene expression 123 
analyses (supplementary figure 1B). 124 
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2) PM control (n=10) vs. OA (n=11) for protein expression analyses (supplementary figure 125 
1C). 126 
Body mass index (BMI; kg/m2) was available for TKR but not PM cases. 127 
Tissue processing and grading 128 
Surgeons and technician (RH) were instructed to collect synovium from the medial joint line 129 
from PM and TKR cases. Fresh synovium was snap-frozen in liquid nitrogen, without 130 
fixation, with replicate samples formalin-fixed and wax-embedded for haematoxylin and 131 
eosin staining and grading for synovitis [9]. Synovial inflammation was graded (0 to 3) only 132 
in samples with synovial lining present. Grade 0 = no synovitis, synovial lining < 4 cells 133 
thick, with few or no inflammatory cells. Grade 1 = mild synovitis, synovial lining 4 or 5 134 
cells thick, with increased cellularity and some inflammatory cells present. Grade 2 = 135 
synovial lining 6 or 7 cells thick, dense cellularity with inflammatory cells (but no lymphoid 136 
aggregates). Grade 3 = severe synovitis; synovial lining more than 7 cells thick, with 137 
inflammatory cell inflammation which may include perivascular lymphoid aggregates and 138 
dense cellularity.  139 
The extent and severity of articular cartilage loss of medial and lateral tibial plateaux and 140 
femoral condyles were graded [17] as follows; grade 0 =   normal: smooth, unbroken surface, 141 
homogeneous white to off-white colour, grade 1 = swelling and softening: a light brown 142 
homogenous colouration, grade 2 = superficial fibrillation lightly broken surface, white to 143 
off-white/light brown in colour, grade 3 = deep fibrillation: coarsely broken cartilage surface, 144 
dark brown, grey or red in colour, grade 4 = subchondral bone exposure: stippled white and 145 
dark brown/red in colour.  The proportion of each articular surface area corresponding to each 146 
grade was used to calculate a chondropathy score (0-100). Scores for each of the 4 147 
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compartments were summated to give a tibiofemoral chondropathy score (0; normal – 400; 148 
complete cartilage loss). 149 
PM delay was calculated as the time (h) between death and opening of the knee for tissue 150 
collection. Cadavers were stored at 4°C.  151 
Gene expression 152 
Total RNA was extracted from snap frozen synovia, homogenised in 1ml of TRI reagent 153 
(Sigma, Poole, UK) and purified according to manufacturer instructions. Total RNA (100ng) 154 
was reverse transcribed to complementary DNA using Affinity Script Reverse Transcriptase 155 
(Agilent Technologies, Stockport, UK) and random primers, according to the manufacturer’s 156 
protocol. The reaction was incubated at 25°C for 10 minutes, then 50°C for 60 minutes and 157 
terminated by incubation at 70°C for 15 minutes. The cDNA was in a total reaction volume 158 
of 28µl.  159 
Gene expression profiling was performed using custom-made 384 well microfluidic cards 160 
(TaqMan® Array Card, Applied Biosystems, Waltham, MA). Each card consisted of 4 161 
reference genes (Beta actin [ACTB], Glyceraldehyde 3-phosphate dehydrogenase [GAPDH], 162 
Hydroxymethylbilane Synthase [HMBS] and Ubiquitin C [UBC]) and 92 target genes, which 163 
were identified as possibly mediating pain through sensitising peripheral nerve terminals 164 
(supplementary table 1).  165 
For each tissue sample a reaction mix was made using 100µl of diluted cDNA (1:4) and 166 
100µl of TaqMan Universal PCR Master Mix. Reaction mix (100µl) was loaded into two 167 
adjacent ports in the microfluidic card which allowing duplicate runs on a 7900HT Fast Real-168 
Time PCR system (Applied Biosystems). RNA expression values are reported as arbitrary 169 
units normalised to reference gene expression.   170 
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Protein expression   171 
The Luminex screening human assay (10-plex) (LXSAH-10, R&D systems) was used to 172 
measure expression of CCL2, CCL5, CCL8, Chemokine ligand 10 (CXCL10), IL1β, IL1R1, 173 
MMP1, MMP7, TNFα, VEGF. Analytes selected for Luminex analysis were those that were 174 
either significantly (P<0.05) or > 3-fold different (in the same direction) between 175 
asymptomatic and symptomatic chondropathy groups in both the discovery and validation 176 
samples. In addition, we included two analytes previously hypothesised to be important in 177 
OA (TNFα and IL1β) [19], and two pro-inflammatory chemokines that were increased in 178 
symptomatic chondropathy compared to non-arthritic controls (CXCL10 and CCL5). 179 
ANXA1 and NFKBIA protein expression were excluded due to non-availability of 180 
compatible reagents. Discovery and validation samples on cases with RNA data in the current 181 
study were together used to compare protein expression between asymptomatic and 182 
symptomatic chondropathy groups.  183 
Total protein was extracted from snap frozen synovia homogenised in 600µl of Cell Lysis 184 
buffer (R&D systems, Abingdon, UK) with protease inhibitor (Sigma), and centrifuged for 5 185 
minutes. Total protein concentration was measured in supernatants (Pierce BCA-200 Protein 186 
Assay Kit, Fisher Scientific, Loughborough, UK). For Luminex analysis the remaining 187 
supernatant was diluted 1:2 with Calibrator Diluent RD6-52. The plate, standards (3-fold 188 
dilution series), microparticle cocktail, biotin antibody cocktail and streptavidin-PE were 189 
prepared according to the manufacturer’s instructions. In brief, the plate was rinsed with 190 
wash buffer and liquid removed using a vacuum manifold. Tissue samples were incubated 191 
(2h, room temperature) with the microparticle cocktail on a microplate shaker, followed by 192 
incubation with Biotin antibody (1h) and Steptavidin-PE (30min), with triplicate washes 193 
between each step. Plates were read using a Bio-Plex® Multiplex Immunoassay System (Bio-194 
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Rad, Hemel Hempstead, UK). Each analyte was adjusted for total protein concentration in 195 
each case. Protein expression is expressed as ng protein of interest per g total protein (ng/g). 196 
 197 
Statistical analysis 198 
Fold changes in gene expression levels were calculated for each tissue sample using the 199 
comparative Ct method (2-∆Ct) where ∆Ct refers to Ct value of each individual target gene 200 
value minus Ct value of the reference gene. ∆Ct values are given as mean (95% confidence 201 
interval [CI]) and using Mann-Whitney U test (asymptomatic vs symptomatic chondropathy 202 
and PM control vs OA). Kruskal Wallis One Way ANOVA with post-hoc pair wise 203 
comparisons compared differences between non-arthritic controls, asymptomatic and 204 
symptomatic chondropathy). Fold increase in gene expression was calculated by dividing the 205 
mean of the symptomatic chondropathy group by the mean of the asymptomatic 206 
chondropathy group, and fold decrease as the inverse of the fold increase. Tissue samples 207 
were excluded from analysis where RNA could not be transcribed to cDNA, or where 208 
reference gene Ct values were outliers (Grubb’s test, Graphpad, San Diego). P< 0.05 was 209 
considered statistically significant, and the false discovery rate (FDR) set at 5%, was used to 210 
correct for multiple testing [20]. 211 
NormFinder (Microsoft Excel add-in) was used to determine the most stable individual 212 
reference gene Ct values, or the most stable geometric mean of different combinations of 213 
reference genes to normalise gene expression.   214 
Binary logistic regression compared between groups reference gene stability and gene 215 
expression associations with covariates (age, gender, BMI and PM delay, each separately 216 
tested in discovery and validation samples combined). Ct values were dichotomised about the 217 
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median as the dependent variable, and analyses adjusted for experiment number, to account 218 
for inherent variability between experimental runs as discovery and validation studies were 219 
conducted on different days. Spearman’s rank correlation was used to determine associations 220 
between protein expression and each parameter (age, gender, BMI, PM delay), and separately 221 
to identify associations between reference gene expression and PM delay.  222 
Multivariable testing was used to adjust for multiple covariates (age, gender and experiment 223 
number) combing discovery and validation sample RNA gene expression data for key 224 
analytes. All gene and protein targets were selected to share associations with inflammation 225 
or sensitisation, and therefore adjustments were not made for other genes or proteins 226 
measured in the same cases within each experiment.  227 
Pseudo R2 values are reported to explain logistic regression model variance (Cox and Snell 228 
R-square and Nagelkerke R-square), and percentages are reported for the number of cases 229 
correctly classified as asymptomatic chondropathy vs. symptomatic chondropathy. Receiver 230 
operator curve (ROC) analysis was used to determine sensitivity, specificity and 95% 231 
confidence intervals for determining classification of asymptomatic or symptomatic 232 
chondropathy cases (StataSE v15). ROC analyses were conducted using one gene at a time 233 
and binary logistic regression was undertaken to produce a predictive variable combining 234 
three genes together. 235 
RESULTS 236 
Patient demographics and joint pathology 237 
Study groups were similar for sex, but symptomatic chondropathy groups were younger than 238 
asymptomatic chondropathy groups in discovery gene expression and proteomics studies 239 
(Table 1). Synovitis scores were higher in symptomatic (median (IQR); 1 (0-3) and 1.5 (0.25-240 
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3)) than in asymptomatic (0 (0-0.5) and 0 (0-0)) chondropathy cases (P=0.05 and 0.005, 241 
respectively for discovery and validation gene expression samples).  242 
PM controls (n=10) selected for comparison of protein expression with OA cases (n=11) 243 
displayed low macroscopic chondropathy scores (median [IQR]; 82 [45-111]) and their 244 
demographics did not significantly differ from OA cases (median (IQR) ages 66 (59-70) and 245 
61 (54-74) years, P=0.86; 60% and 27% male, P=0.20). Histological synovitis was absent 246 
(grade 0) in 9/10 PM control cases and mild (grade 1) in 1 case. Cases in the OA group all 247 
displayed moderate or severe synovitis (grades 2 or 3).  248 
[TABLE 1]249 
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Reference gene expression 250 
Ct expression for each of the 4 reference genes was not significantly different between PM 251 
and TKR cases (asymptomatic and symptomatic chondropathy groups, respectively, P≥0.42) 252 
and their geometric mean was used for normalisation (supplementary Table 2). PM delay (h) 253 
was not associated with the Ct values of any of the four reference genes; ACTB, GAPDH, 254 
HMBS and UBC (P = 0.98, 0.74, 0.70, 0.68). Final study numbers/group are reported in table 255 
1, (see table 1 legend for an explanation of exclusions). 256 
Synovial gene and protein expression patterns associated with symptomatic OA 257 
Synovial gene expression in symptomatic OA 258 
In the discovery samples, following corrections for multiple testing (FDR = 5%, P≤0.01) 8 259 
genes were significantly upregulated and 12 significantly down-regulated in symptomatic 260 
compared to asymptomatic chondropathy cases (supplementary Table 3). In the validation 261 
samples, 2 genes were significantly up-regulated and one significantly down-regulated 262 
(supplementary Table 4). Table 2 shows genes which were differentially expressed in the 263 
same direction in both discovery and validation samples. 264 
CCL2, CCL8 and ANXA1 were up-regulated in symptomatic chondropathy cases in both 265 
discovery and validation samples (Table 2) but did not reach statistical significance after 266 
FDR correction. In addition, MMP1 expression was >3-fold higher in symptomatic 267 
chondropathy cases across both samples, reaching statistical significance in the discovery 268 
sample. IL1R1 and NFKBIA gene expressions were down-regulated in symptomatic 269 
chondropathy cases in both discovery and validation samples, IL1R1 remaining significant 270 
after FDR correction in both samples. MMP7 and VEGFA expressions were >3-fold lower in 271 
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symptomatic chondropathy cases in both discovery and validation samples, VEGFA was 272 
significantly downregulated in the discovery sample (P= 0.001). 273 
 274 
[Table 2]  275 
 276 
 277 
Synovial protein expression in symptomatic OA 278 
Five analytes were significantly differentially expressed at the protein level between groups 279 
(Figure 1, Table 3). Of these, CCL5 and MMP1 were greater, whereas VEGF, CXCL10 and 280 
IL1R1 were each lower in symptomatic than in asymptomatic chondropathy cases. 281 
 282 
[Figure 1] 283 
[Table 3] 284 
 285 
Synovial gene and protein expression patterns associated with OA disease status 286 
In order to explore whether differences in gene and protein expression between symptomatic 287 
and asymptomatic OA represented characteristics of OA disease, we compared OA samples 288 
obtained at TKR with post mortem samples from people without known arthritis. 289 
Synovial gene expression 290 
Gene expression is compared between groups in supplementary table 4. Several genes were 291 
upregulated in symptomatic chondropathy compared to non-arthritic control groups (fold 292 
increase, P); ANXA1 (1.90, P<0.001), ANXA6 (2.30, P=0.001), CCL2 (2.25, P=0.042), CCL5 293 
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(3.30, P=0.001), CMKLR1 (4.25, P=0.02), CTGF (3.06, P=0.001), CXCL10 (6.28, P=0.001) 294 
and FOS (6.87, P<0.001). F2RL3 (32.25, P<0.001), IL1R1 (1.84, P=0.02) and NFKBIA (3.52, 295 
P=0.04) were decreased in symptomatic chondropathy compared to non-arthritic control 296 
groups. 297 
Synovial protein expression in OA 298 
CCL8 and MMP1 protein immunoreactivities were significantly increased in the synovium of 299 
the OA compared to PM control groups (Figures 2B&C), whereas CCL2, VEGF, CXCL10 300 
IL1R1 and CCL5 did not reach statistical significance (Figures 2A, D-G). 301 
 302 
[Figure 2] 303 
 304 
Contribution of synovial molecular expression to classification of symptomatic and 305 
asymptomatic chondropathy  306 
To evaluate the possible direct contributions of synovial molecular expression to the presence 307 
or absence of symptoms in OA we first explored possible effects of measured confounding 308 
factors, and then evaluated the relative contributions of gene expression for 3 identified key 309 
molecules (IL1R1, MMP1 and VEGFA) to classification of symptomatic and asymptomatic 310 
chondropathy cases.  311 
Possible effects of age, gender, post-mortem delay or body mass index on protein or gene 312 
expression, separately were explored; only IL1R1 gene expression was associated with age 313 
and CXCL10 with gender (supplementary table 5).  314 
When gene expression data from discovery and validation samples, analysed within a single 315 
model, were adjusted for age, gender and experiment number, the following were 316 
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significantly increased in symptomatic chondropathy cases compared to asymptomatic cases; 317 
CCL2 (2.01-fold, P = 0.01), CCL8 (4.46-fold, P = 0.007), IL1β (1.93-fold, P = 0.021) and 318 
MMP1 (11.6-fold, P = 0.03).  IL1R1 and VEGFA RNA were significantly decreased (2.67-319 
fold, P = 0.016, and 4.79-fold, P = 0.017, respectively) in symptomatic chondropathy vs. 320 
asymptomatic chondropathy. CCL5, CXCL10, MMP7 and TNFα RNA were not significantly 321 
different between groups P = 026, 0.11, 0.17 and 0.26, respectively.  322 
The logistic regression model exploring association of symptomatic vs. asymptomatic 323 
chondropathy with expression of each identified gene was adjusted for age, gender and 324 
experiment number. For IL1R1 the model explained between 58% (Cox and Snell R-square) 325 
to 78% (Nagelkerke R-square) of the variance and correctly classified 87% of cases. For 326 
MMP1 the logistic regression model explained between 49% (Cox and Snell R-square) to 327 
65% (Nagelkerke R-square) of the variance and correctly classified 80% of cases. For 328 
VEGFA the logistic regression model explained between 49% (Cox and Snell R-square) to 329 
66% (Nagelkerke R-square) of the variance and correctly classified 87% of cases. A 330 
combined logistic regression model (which included MMP1, IL1R1 and VEGFA, adjusted for 331 
age, gender and experiment number), explained between 75% (Cox and Snell R-square) to 332 
100% (Nagelkerke R-square) variance, and correctly classified 100% of cases in symptomatic 333 
and asymptomatic chondropathy groups. Similarly, ROC analyses indicated that 90% of 334 
cases were correctly classified using combined expression of the 3 genes, with sensitivity and 335 
specificity of 85-95% (supplementary table 6). 336 
 337 
 338 
 339 
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DISCUSSION 340 
We have identified synovial molecular expression patterns that are associated with 341 
symptomatic OA by comparing TKR cases (symptomatic chondropathy) with PM cases with 342 
similar macroscopic joint surface appearances who had not sought help for knee pain 343 
(asymptomatic chondropathy). Additionally, we have identified synovial molecular 344 
expression patterns that are associated with OA disease status, by comparing aged-matched 345 
PM and TKR cases. 346 
Up-regulation of MMP1 in concert with the down-regulation of VEGFA and IL1R1 might 347 
reflect molecular pathways that mediate OA symptoms. MMP1 (collagenase-1) is a secreted 348 
metalloproteinase which catalyses cleavage of matrix collagens in OA. MMP1 gene and 349 
protein expression were increased in association with OA disease status in the synovia of OA 350 
compared to PM controls. MMP1 is induced in synovial fibroblasts in response to pro-351 
inflammatory mediators such as IL1β and TNFα [21]. Synovium, as well as chondrocytes, 352 
might contribute to increased synovial fluid MMP1 levels observed in OA [22]. Association 353 
of MMP1 expression with symptomatic disease is unlikely to be entirely explained by 354 
cartilage structural damage because our cases and controls were matched for severity of 355 
macroscopic chondropathy. Urinary collagen degradation products, generated by the action of 356 
collagenases, have also been associated with OA pain[23]. Increased MMP1 might be a 357 
marker of cytokine-driven inflammation, which may in turn lead to a cascade of events that 358 
sensitise peripheral nerve terminals in the synovium, whilst exacerbating cartilage damage. 359 
IL1β is produced by OA synovium, even in early disease[24]. IL1β was upregulated in 360 
symptomatic compared to asymptomatic chondropathy cases. The pro-inflammatory actions 361 
of IL1β are exerted through binding its membrane receptor, interleukin-1 receptor (IL1R1). 362 
Increased IL1R1 expression was previously found in OA synovial fibroblasts, compared to 363 
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normal controls [25]. IL1R1 expression can be downregulated during activation by IL1β [26]. 364 
Our data suggest downregulation of IR-1R1 in OA synovium compared to non-arthritic 365 
controls, and, in particular in symptomatic compared with asymptomatic chondropathy, 366 
consistent with increased IL1β/IL1R1 pathway activity. Decreased IL1R1 mRNA in 367 
symptomatic chondropathy was replicated across both discovery and validation samples, and 368 
at the protein level. IL1β/IL1R1 pathway activation might therefore have particular relevance 369 
for OA symptoms.  Studies using OA animal models report favourable benefits of IL-1 receptor 370 
antagonist therapy [27, 28]; however clinical trials in humans reported no improvement in pain 371 
([29, 30]).Antibodies specifically targeted at IL1R1 did not achieve clinical important 372 
symptomatic benefit compared to placebo [29]. Our data raise the possibility that IL1R1 373 
downregulation prior to treatment might have contributed to these negative results, and 374 
earlier phases of OA synovitis might respond differently to IL1β/IL1R1 pathway inhibition. 375 
Furthermore, IL1β/IL1R1 pathway inhibition might only be effective for a subset of people 376 
with OA whose pain is mediated by synovitis. 377 
Increased VEGF in synovium, cartilage, synovial fluid and plasma might contribute to 378 
synovitis and osteophyte formation in OA[31]. VEGF might also contribute to OA pain 379 
through facilitating inflammation and by actions on sensory nerves[32, 33]. Perhaps 380 
surprisingly, we found that VEGFA was decreased at the gene and protein level in patients 381 
with symptomatic compared to asymptomatic chondropathy. VEGF exists as multiple 382 
isoforms dependant on alternative splicing of mRNA [34]. VEGFAa isoforms contribute to 383 
angiogenesis and pain, whereas VEGFAb isoforms might be anti-angiogenic and analgesic. 384 
Further studies should explore whether reduced VEGF expression observed in the current 385 
study reflects an alteration in isoform balance that might contribute to OA pain. 386 
We found associations of symptomatic chondropathy with a range of additional chemokines, 387 
cytokines and metalloproteinase, although associations were less consistent at gene and 388 
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protein expression levels than with MMP1, IL1R1 and VEGF. The small sample sizes in the 389 
current study might have led us to overlook biologically important associations, although our 390 
repository of joint samples from >3000 cases was required to select sample groups with 391 
adequate matching for severity of structural chondropathy and other factors. Further research 392 
should explore mechanisms by which CCL2, CCL8, CCL5, CXCL10, TNF-α and MMP7 393 
might contribute to OA pain. 394 
CCL2 and CCL8 gene expressions were higher in symptomatic OA vs non-arthritic controls 395 
(CCL8 protein was also higher in OA vs. PM controls), and in symptomatic knee OA 396 
compared to chondropathy-matched asymptomatic post mortem cases. CCL2 and CCL8 each 397 
serve as ligands for chemokine receptor 2 (CCR2) [35]. CCL2 from synovial fibroblasts [36] 398 
recruits and activates inflammatory cells to sites of inflammation [37] and CCL2 mRNA and 399 
protein are upregulated in osteoarthritic tibiofemoral joints [38]. Synovial fluid CCL2 has 400 
been associated with OA knee pain severity, in addition to physical disability [39]. During 401 
inflammation, elevated expression of CCL2 might act on sensory nerves to activate transient 402 
receptor potential cation channel subfamily V member 1 (TRPV1) to induce hyperalgesia 403 
[40]. CCL8 has previously been detected in fibroblasts and macrophages in the synovial 404 
lining of arthritic patients [35]. Mice that lacked the CCL2 receptor (CCR2) were protected 405 
against movement-provoked pain following surgical induction of OA [41]. Together these 406 
data indicate the CCL2, CCL8 and CCR2 pathway as possible targets for OA pain. 407 
Our study is necessarily subject to a number of limitations. Both RNA and proteins are  408 
susceptible to degradation by post-mortem processes, and RNA by RNAses [42]. However, 409 
we did not identify associations between gene or protein expression levels and time from 410 
death to tissue processing for any of the replicated genes taken forward for Luminex analysis. 411 
Furthermore, there were no significant differences in the expression of the 4 reference genes 412 
between surgical and post-mortem groups. Target gene expression was also normalised to 413 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
reference genes to compensate for any heterogeneity of quality between tissue samples. 414 
Genes might be activated post-mortem, however this has only been shown in animal studies 415 
and not yet with human tissue [43]. OA is strongly associated with age, and it can be difficult 416 
to distinguish between OA pathological change and age-related changes or senescence. 417 
However, we found associations of gene and protein expression with disease status in age-418 
matched cases, and associations with symptomatic chondropathy were not affected by 419 
adjustment for chronological age, except for IL1R1. Gene expression and protein levels alone 420 
need not necessarily indicate protein activity. We validated key molecular targets identified 421 
through gene expression studies using a complimentary proteomics approach, but future 422 
studies should explore functional activity. We investigated a large number of proteins and 423 
genes, and some statistically significant associations might have occurred by chance. In order 424 
to reduce this risk, we undertook analyses to adjust for multiple testing by applying a 425 
correction for FDR [20]. Furthermore our study design comprised of initial exploratory 426 
analysis (discovery RNA study), which was then validated using a separate set of 427 
asymptomatic and symptomatic chondropathy cases. Our main conclusions are based on 428 
results from across independent case samples used for discovery and validation gene 429 
expression studies and supported by protein expression data. Genes and proteins were 430 
selected for study due to their potential roles in inflammation and neuronal sensitisation, and 431 
identified targets might be markers for other associated inflammatory or sensitising factors. 432 
The high pseudo R2 values obtained in this study suggest that, when severity of chondropathy 433 
is matched, a high proportion of model variance for allocation to symptomatic or 434 
asymptomatic chondropathy groups might be explained by synovial gene and protein 435 
expression. This suggests that gene and protein expression might be biologically important, 436 
but targets identified through these studies require further exploration either as biomarkers, or 437 
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as treatment targets for managing OA pain. However, it is important to note that the high 438 
pseudo R2 values may be representing an overfitted model. 439 
In conclusion, symptomatic OA was associated with an up-regulation in synovium of MMP1 440 
and decrease of IL1R1 and VEGFA compared to asymptomatic chondropathy cases with 441 
similar macroscopic joint surface appearances who did not seek TKR. Synovial inflammation 442 
is a feature of symptomatic OA, and better understanding of the gene expression patterns 443 
could lead to refinement of existing therapies and development of new treatments to reduce 444 
pain. This work was a target generating exercise. Further work is necessary to determine 445 
whether molecular targets that we have identified are biologically or clinically important, or 446 
may eventually lead to treatment strategies aiming to alleviate OA symptoms. 447 
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FIGURE LEGENDS 624 
Figure 1: Protein expression in synovia from chondropathy cases classified as either 625 
asymptomatic or symptomatic. Groups were matched for macroscopic chondropathy scores. 626 
A: CCL2 (chemokine ligand 2), B: CCL5 (chemokine ligand 5). C: MMP1 (matrix 627 
metalloprotease 1), D: VEGF (vascular endothelial growth factor-A), E: CXCL10 628 
(chemokine ligand 10), F: IL1R1 (interleukin 1 receptor 1). Median (IQR) are shown. IL1β, 629 
TNFα, MMP7 and CCL8 immunoreactivities were below the lower limit of detection. 630 
Figure 2: Protein expression for selected genes compared between PM control and OA cases 631 
undergoing arthroplasty. A: CCL2 (chemokine ligand 2), B: CCL8 (chemokine ligand 8) C): 632 
MMP1 (matrix metalloprotease 1), D: VEGF-A (vascular endothelial growth factor-A), E: 633 
CXCL10 (chemokine ligand 10), F: IL1R1 (interleukin 1 receptor 1) and G: CCL5 634 
(chemokine ligand 5). Data expressed as median (IQR). MMP7, IL1β and TNFα 635 
immunoreactivities were below the lower limit of detection. 636 
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TABLES 638 
Table 1 Clinical and pathological characteristics of the study groups 639 
Tissues were obtained at the time of total knee replacement for OA (symptomatic chondropathy) or were obtained post mortem (asymptomatic chondropathy 640 
and non-arthritic controls). Results are reported for groups following exclusions for outlier reference genes, or inability to transcribe RNA to cDNA. In the 641 
discovery RNA study, 1 asymptomatic chondropathy case was excluded due to inability to transcribe RNA to cDNA (low RNA concentration) and one 642 
symptomatic chondropathy case due an outlier reference gene Ct value (final numbers, 11/group). In the validation study, the following were excluded from the 643 
final analysis; 3 non-arthritic controls, (low RNA concentration), 2 asymptomatic chondropathy cases (one low RNA concentration, the other due to an outlier 644 
reference gene Ct value) and 1 symptomatic chondropathy cases (low RNA concentration). Final numbers for the validation study were 7 non-arthritic controls, 645 
8 asymptomatic chondropathy and 9 symptomatic chondropathy. Protein expression conducted on one extra asymptomatic chondropathy and symptomatic 646 
chondropathy case that were excluded from the final RNA analysis (due to outlier reference genes). Asymptomatic and symptomatic chondropathy cases were 647 
successfully matched for macroscopic chondropathy scores. ‡Post-mortem delay was calculated as the time (h) between death and tissue collection. Data 648 
 Discovery sample  Validation sample  Protein expression 
Chondropathy  Non-
arthritic 
controls 
Chondropathy  Chondropathy  
Asymptomatic Symptomatic P  Asymptomatic Symptomatic P  Asymptomatic Symptomatic P  
n 11 11  7 8 9  20 21  
Age, years 79 (65-88) 61 (54-73) 0.005 64 (49-74) 67 (52-78) 64 (55-72) 0.756 74 (64-85) 64(35-82) 0.026 
% male 36 46 0.748 43 25 35 0.774 35 43 0.611 
BMI, kg/m2 NA 33 (31-39) NA NA NA 31 (28-36) NA NA 32 (29-37) NA 
Post-mortem delay 
(h)‡ 
58 (29-89) NA NA 55 (29-64) 66 (44-79) NA NA 64 (35-82) NA NA 
Macroscopic 
chondropathy score 
(scale range 0-400) 
214 (204-229) 223 (213-239) 0.300 55 (44-97) 197 (163-204)* 195(171-203)^ 0.001 205 (195-223) 208(188-231) 0.698 
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expressed for included cases as median (IQR) or %. Differences between asymptomatic and symptomatic chondropathy groups in the discovery sample and in 649 
the proteomics analysis were comparing using Mann Whitney tests. Differences between non-arthritic controls, asymptomatic chondropathy, and symptomatic 650 
chondropathy groups in the validation sample were compared using Kruskal Wallis One Way ANOVA. *P = 0.006 vs non-arthritic controls, ^P = 0.003 vs 651 
non-arthritic controls. BMI; body mass index, NA; not available. 652 
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Table 2: Genes which were differentially expressed in the synovium of symptomatic chondropathy 653 
cases compared to asymptomatic chondropathy cases in discovery and validation samples. 654 
 Discovery sample Validation sample  
 Fold change P Fold change P 
Up-regulated 
ACE 2.05 0.01 1.81 .059 
ANXA1 1.41 0.04 1.30 .021 
CASP1 2.90 <0.001 1.45 .139 
CCL2 1.65 0.013 3.57 .004 
CCL3 2.02 0.056 3.21 .167 
CCL4 1.91 0.023 1.98 .236 
CCL5 1.40 0.034 1.07 .606 
CCL8 3.87 0.016 6.28 .000082* 
CMKLR1 1.99 0.008 2.06 .167 
CNR2 2.85 0.088 1.39 .481 
CTGF 2.22 0.003 1.61 .139 
CTSK 1.19 0.562 1.37 .236 
CXCL10 5.81 0.133 2.08 .277 
EPHX2 1.68 0.034 1.07 .370 
FOS 2.03 0.056 5.16 .001 
IL10 2.31 0.023 2.62 .059 
IL1B 1.29 0.519 3.85 .036 
IL6 1.01 0.401 2.40 .370 
JUN 1.23 0.171 1.49 .139 
MMP1 13.93 <0.001* 4.66 .888 
MMP3 4.15 0.116 1.27 .606 
S100A8 1.43 0.243 1.49 .888 
TG 1.08 0.606 1.51 .963 
TREM1 1.23 0.652 1.33 .743 
TRPV4 1.45 0.088 1.25 .888 
Down-regulated 
CX3CL1 2.72 <0.001 1.62 0.167 
CXCL2 2.71 0.013 2.40 0.036 
CXCL5 3.36 0.056 2.50 0.481 
F2RL3 7.45 0.101 9.65 0.004 
IL1R1 2.07 0.001* 3.32 0.001* 
IL8 2.86 0.056 1.95 0.423 
KDR 2.33 0.01 1.28 0.093 
LTB4R 2.29 0.007 1.87 0.093 
MMP7 4.91 0.034 11.62 0.541 
MMP9 1.56 0.699 5.58 0.277 
NFKBIA 2.37 0.0003* 3.79 0.006 
NOS3 2.20 0.019 1.42 0.423 
S100A9 2.12 0.606 1.34 0.277 
SOCS1 2.70 0.002 1.11 0.815 
SOCS3 2.23 0.056 1.49 0.277 
STAT3 1.11 0.652 2.06 0.114 
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TNFRSF11B 1.27 0.562 1.45 0.321 
VEGFA 8.15 <0.001* 4.08 0.139 
Up or down regulation references symptomatic compared to asymptomatic chondropathy cases. Genes 655 
shown are those which were increased or decreased in the same direction in both discovery and validation 656 
samples; see supplementary tables 3 & 4 for additional analytes. Bold indicates genes selected for analysis 657 
of protein expression based on concordant findings between discovery and validation samples (p<0.05 658 
or >3-fold difference between symptomatic and asymptomatic chondropathy groups). *P<0.01 after FDR 659 
(5%) corrections in the discovery sample and <0.0001 in the validation sample. Gene expression is 660 
normalised to the geometric mean of all 4 reference genes. 661 
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Table 3: Overall summary of key molecular targets associated with symptomatic OA. 663 
Target RNA Discovery  RNA Validation Protein 
  
Fold change  P  Fold change P  Fold change P 
MMP1: Matrix 
Metalloprotease 1* 
13.93 increased in 
Symptomatic chondropathy 
<0.001 4.66 increased in  
Symptomatic 
chondropathy 
0.888 2.92 increased in  
Symptomatic 
chondropathy 
0.001 
IL1R1: Interleukin 1 
receptor, type I* 
2.07 decreased in  
Symptomatic chondropathy 
0.001 3.32 decreased in  
Symptomatic 
chondropathy 
0.001 1.68 decreased in  
Symptomatic 
chondropathy  
0.003 
VEGF: Vascular endothelial 
growth factor A* 
8.15 decreased in  
Symptomatic chondropathy  
<0.001 4.08 decreased in  
Symptomatic 
chondropathy 
0.139 3.63 decreased in  
Symptomatic 
chondropathy 
<0.001 
CCL2: Chemokine Ligand 2 1.65 increased in  
Symptomatic chondropathy  
0.013 3.57 increased in  
Symptomatic 
chondropathy 
0.004 1.46 decreased in  
Symptomatic 
chondropathy 
0.192 
CCL8:  Chemokine Ligand 8 3.87 increased in  
Symptomatic chondropathy  
0.016 6.27 increased in  
Symptomatic 
chondropathy 
<0.001 NA NA 
IL-1β: Interleukin 1-beta 1.29 increased in  
Symptomatic chondropathy  
0.519 3.85 increased in  
Symptomatic 
chondropathy 
0.036 NA NA 
TNF-α: Tumour necrosis 
factor-alpha  
3.86 increased in  
Symptomatic chondropathy  
<0.001 1.25 decreased in  
Symptomatic 
chondropathy 
0.815 NA NA 
MMP7:  Matrix 
Metalloprotease 7 
4.908 decreased in  
Symptomatic chondropathy  
0.034 11.62 decreased in TKR 0.541 NA NA 
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* Genes that satisfy the following criteria 1)increased in the same direction in both the original and replication RNA study, 2) P<0.05 or fold 664 
change >3 and 3) significantly differentially expressed at the protein level. 665 
 666 
 667 
CCL5: Chemokine ligand 5 1.40 increased in  
Symptomatic chondropathy  
0.034 1.07 increased in TKR 0.606  1.86 increased in TKR 0.015 
CXCL10: Chemokine (C-X-C 
motif) ligand 10) 
5.81 increased in  
Symptomatic chondropathy 
0.133 2.08 increased in TKR 0.277 1.97 decreased in TKR 0.019 
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 668 
Figure 1: Protein expression in synovia from chondropathy cases classified as either 669 
asymptomatic or symptomatic. Groups were matched for macroscopic chondropathy scores. 670 
A: CCL2 (chemokine ligand 2), B: CCL5 (chemokine ligand 5). C: MMP1 (matrix 671 
metalloprotease 1), D: VEGF (vascular endothelial growth factor-A), E: CXCL10 672 
(chemokine ligand 10), F: IL1R1 (interleukin 1 receptor 1). Median (IQR) are shown. IL1β 673 
(interleukin 1 beta), TNF-α (tumour necrosis factor alpha), MMP7 (matrix metalloprotease 7) 674 
and CCL8 (chemokine ligand 8) immunoreactivities were below the lower limit of detection. 675 
 676 
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 677 
Figure 2: Protein expression for selected genes compared between PM control and OA cases 678 
undergoing arthroplasty. A: CCL2 (chemokine ligand 2), B: CCL8 (chemokine ligand 8) C): 679 
MMP1 (matrix metalloprotease 1), D: VEGF-A (vascular endothelial growth factor-A), E: 680 
CXCL10 (chemokine ligand 10), F: IL1R1 (interleukin 1 receptor 1) and G: CCL5 681 
(chemokine ligand 5). Data expressed as median (IQR). MMP7 (matrix metalloprotease 7), 682 
IL1β (interleukin 1 beta) and TNF-α (tumour necrosis factor alpha) immunoreactivities were 683 
below the lower limit of detection. 684 
 685 
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